Article
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.
Science China. Life sciences - 1 Aug 2026
Zhuang Wei, Bai Hua, Zhao Jie, Li Weihua, Yu Jiaojiao, Wang Zhijie, Duan Jianchun, Hao Xuezhi, Wang Yan, Liu Yutao, Wang Lin, Lin Lin, Wan Rui, Sun Boyang, Xu Jiachen, Fei Kailun, Fan Yaguan, He Wenting, Liu Zheng, Fan Linjie, He Danming, Gao Ruolin, Yang Yuanyuan, Ying Jianming, Zhong Jia, Wang Jie
Abstract excerpt
Epidermal growth factor receptor (EGFR) exon 19 deletions (19del) in non-small cell lung cancer (NSCLC) confer sensitivity to tyrosine kinase inhibitors (TKIs). However, the efficacy of the individual EGFR 19del variant remains unclear. This study aims to dissect the structural disparities of various EGFR 19del mutations and associate these variations with clinical outcomes. Here, a total of 399 patients from two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.